Related Experiment Videos
Diabetes mellitus-cell transplantation and gene therapy approaches
1UCSD Cancer Center, La Jolla, CA 92093-0912, USA.
Abstract:
Diabetes mellitus affects millions of people in the United States and worldwide. It has become clear over the past decade that the chronic complications of diabetes result from lack of proper blood glucose concentration regulation, and particularly the toxic effects of chronic hyperglycemia on organs and tissues. Pancreas transplants can cure insulin-dependent diabetes mellitus (IDDM). Furthermore, recent advances in pancreatic islet isolation and immunosuppressive regimens have resulted in dramatic improvements in the survival and function of islet allografts. Therefore, islet replacement strategies are becoming increasingly attractive options for patients at risk for severe diabetic complications. A major limitation of these approaches is the small number of organs available for transplantation or islet isolation. Thus, an important next step in developing curative treatments for type I diabetes will be the generation of a replenishable source of glucose-responsive, insulin-secreting cells that can be used for beta cell replacement. This review focuses on approaches to developing robust and widely applicable beta-cell replacement strategies with an emphasis on manipulating beta-cell growth and differentiation by genetic engineering.
Insights
Generating a replenishable source of insulin-producing beta cells is crucial for curing type 1 diabetes. Genetic engineering approaches to manipulate beta-cell growth and differentiation are key to developing effective cell replacement therapies.
Area of Science:
- Endocrinology
- Regenerative Medicine
- Genetic Engineering
Background:
- Diabetes mellitus, particularly insulin-dependent diabetes mellitus (IDDM), affects millions globally, with chronic complications arising from poor blood glucose regulation and hyperglycemia.
- Pancreas transplantation and islet allografts offer potential cures for IDDM, showing improved survival and function due to advances in isolation techniques and immunosuppression.
- A significant limitation to these cell replacement strategies is the scarcity of donor organs for transplantation or islet isolation.
Purpose of the Study:
- To review strategies for developing robust and widely applicable beta-cell replacement therapies for type 1 diabetes.
- To focus on the potential of genetic engineering to manipulate beta-cell growth and differentiation for therapeutic purposes.
Main Methods:
- Review of current research on pancreatic islet isolation and transplantation.
- Analysis of advancements in immunosuppressive regimens for islet allografts.
- Exploration of genetic engineering techniques to control beta-cell proliferation and differentiation.
Main Results:
- Recent advances have improved islet allograft survival and function, making islet replacement an attractive option.
- The limited availability of donor organs remains a major obstacle for widespread therapeutic application.
- Genetic engineering presents a promising avenue for generating a replenishable source of functional beta cells.
Conclusions:
- Developing a sustainable source of glucose-responsive, insulin-secreting cells is essential for curative type 1 diabetes treatments.
- Genetic manipulation of beta-cell growth and differentiation holds significant potential for future cell replacement strategies.
- Further research in beta-cell regeneration and genetic engineering is critical for overcoming current limitations in diabetes therapy.